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Immunological aspects of neoplastic diseases 
V. Radhakrishna, M.D.* 
The immunological approach to neoplas-
tic disease is gaining favor because malig-
nant tumors are associated with Immuno-
deflclent states. Mesenchymal tumors have 
been seen in renal allograft recipients. The 
discovery of carcinoembryonic antigen, al-
fafetoprotein and other protein antigens as-
sociated with malignant diseases are other 
factors. Spontaneous regression of ma-
lignant neoplasm has been attributed to 
an effective immunologic process In the 
host. Identification of tumor specific anti-
gens may explain these spontaneous tumor 
regressions. 
It may not be too optimistic to expect 
tumor vaccine of some sort within the next 
few years. 
B.C.G. and other nonspecific Immu-
nostlmulants are under Investigation for 
treatment of malignant tumors. Transfer fac-
tor has been extensively used in the last 20 
years and seems to be useful in certain types 
of tumors. Immune RNA may be a reason-
able approach to adoptive transfer of 
immunity. 
AF 
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GROUND 1950 the concept developed 
that cancer might be due to the deletion of 
some components necessary for maintain-
ing normal relationship between cells in a 
tissue. The term "surveillance" was first 
coined by Burnet' based on the occurrence 
of spontaneous tumors in renal transplanta-
tion patients who were receiving long-term 
immunosuppressive therapy. He hypoth-
esized that a clone of malignant cells arises 
at regular intervals in all individuals, but 
cells are rejected as allografts unless there is 
some unspecif ied defect in immune re-
sponse. This certainly is a stimulating idea 
but it is still not clear how we are protected 
f rom oncogenic events by the immune 
mechanism. 
Tumor antigens 
O fa l l the parts that theoretically may be 
transformed in malignancy, the cell surface 
may be the most important The discovery of 
tumor specific andgens (TSA) on the cell 
surface may permit early diagnosis.^ Al-
though TSA are probably not only confined 
to the surface, they are most readily detected 
on intactcells. Moreover,TSAonthe surface 
are sensitive to the immune response which 
may result in tumor destruction. 
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(a) Tumor specific antigens. Immunologi-
cal methods which are specific, sensitive 
and relatively inexpensive may soon be the 
best means to d iagnose cancers that produce 
distinctive antigens. Unfortunately, all can-
cers are not alike in this respect, so only 
some of them may be detected by immu-
nological means. In chemically induced tu-
mors, the new tumor antigens are different 
for each tumor. Even two tumors induced in 
the same animal by the same carcinogen 
appear to be antigenically different from 
each other (Figure 1). 
tumor specific ant igens 
tumor speci f ic ant igens 
Figure 1 
Tumor antigens induced by chemical car-
cinogens. When cells of identical genetic back-
ground are transformed with the same chemical 
carcinogen, each new tumor has its own anti-
genic specificity which is not shared with other 
tumors. (Immunology monograph by Upjohn Co. 
1975) 
On the other hand, animal tumors induc-
ed by viruses develop a new antigen that is 
common to all the tumors induced by the 
same virus, even though the tissue origins of 
tumors are different (Figure 2). Both DNA 
and RNA viruses can induce these antigen 
specific tumors. Among DNA viruses that 
can code for new antigens are herpes vir-
uses, adenoviruses, plyoma and papilloma 
viruses. Two groups of viruses have been 
consistently associated with naturally occur-
ring cancer—oncornaviruses containing 
single stranded RNA, and herpes virus with 
double stranded DNA. 
The most important characteristic of on-
cornaviruses is that they contain DNA poly-
merase (Reverse Transcriptase). This enzyme 
reverses the usual direction of information 
( D N A ^ RNA) so that DNA is produced for 
RNA template. This DNA intermediate is 
then integrated with the host genome, caus-
ing neoplastic transformation by some un-
known mechanism. 
In man, Epstein-Barr virus (herpes group) 
has been associated with Burkitt's lympho-
ma, n a s o p h a r y n g e a l c a r c i n o m a and 
Hodgkin's disease. One of the most exten-
sively studied virus-associated cancers is 
carcinoma of cervix, where there is a con-
stant elevation of herpes simplex Type II 
virus antibodies in patients. 
There is good circumstantial evidence that 
RNA and DNA viruses cause cancer. ' 
Whether or not cancer develops following 
exposure to these viruses probably depends 
on the immunologic response ofthe infected 
animal. Spontaneously occurring tumors 
were long considered to lack TSA. The exact 
nature of TSA is not known but it may be part 
of virus particles or component of tumor 
cells.' 
(b) Carcinoembryonic antigen (CEA). In 
1965 Gold demonstrated the presence of a 
glycoprotein antigen in patients with cancer 
of the colon." Subsequently this antigen was 
shown to be present in up to 97% of such 
patients with metastasis.^ Further studies re-
vealed that the levels of CEA vary with the 
stage ofthe disease. In three series of studies 
the CEA level varied from a low of 19% to 
40% in patients with localized disease to a 
high of 100% in patients with disseminated 
disease, especially of the l i v e r . B u t the 
greatest limitation of screening by CEA is its 
nonspecif icity for cancer ofthe colon. Many 
other types of cancers have elevated levels 
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part ic les 
Figure 2 
Three new antigens in a virus transformed cell. Virus capsid antigen and new virus particles may be found 
in the malignant transformed cell recently infected and destined to undergo lysis. (Immunology 
monograph by Uplohn Co. 1975) 
of CEA. For example, CEA is elevated in as 
many as 90% of patients with pancreatic 
carcinoma^ (Table 1). Nor is elevated CEA 
limited to malignant diseases. Many benign 
disorders also have higher levels of CEA 
(Table II) especially liver disease, alcoholic 
pancreatitis and benign obstructive jaun-
dice.' Most patients with inactive ulcerative 
colitis have normal levels of CEA. Elevated 
levels tend to correlate with exacerbation of 
activity.'' Screening for CEA levels is most 
useful in postoperative follow-up of patients 
with colonic carcinoma. Many investigators 
have confirmed that elevated CEA levels fell 
to normal after resection of tumor. 
Postoperative serial CEA determinations 
may identify metastases before clinical evi-
dence of spread of the disease. 
Generally speaking, higher levels of CEA 
are associated w i th poorer prognosis. 
However, several investigators confirm that 
normal levels of CEA do not preclude prim-
ary, metastatic or recurrent disease.^-' 
(c) Alphafetoprotein (AFP). The associa-
tion of AFP with primary liver cancer was 
observed more than ten years ago." Though 
originally thought to be specific for primary 
hepatoma, AFP has been found to be ele-
vated in several other conditions, including 
some normal individuals' (Table 111). In prim-
ary hepatoma up to 70% of patients have 
e l e v a t e d AFP; 8 0 % o f pa t i en ts w i t h 
teratocarcinoma and a small percentage of 
patients with pancreatic, gastric, colonic 
carcinoma also have elevated AFP levels.''''° 
(d) Other Tumor Antigens 
i) A l f a i - H Feto Protein is immuno-
logically identical to ferritin and is present in 
the liver and serum of the human fetus.'" 
Though initially detected in about 60% of 
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CEA Positivity in Cancer Table 1 
Cancer 
Incidence of Positive Assays 
Percentage Mo, cl CaM^ s 
Colon & Rectum 73 316 
Pancreas 92 52 
Uver 67 18 
Breast 52 159 
Cervix 42 45 
Endometrium 27 11 
Ovary 35 20 
Testis 57 29 
Prostate 40 93 
Kidney 35 26 
Bladder 33 106 
Neuroblastoma IX 6 
Leukemia 22 27 
Lymphoma 25 14 
Bronctius 72 90 
Compilation of reported observations made with Gold, Hansen 
or Todd assays from reports by Zamcheck. Lo Gerlo, Reynoso, 
and Laurence, frtodified from Laurence and Neville. 
patients with primary hepatoma, 50% of 
patients w i th various mal ignancies and 
20-30% of certain benign disorders have 
elevated alfa2 — H fetoprotein levels. In chil-
dren hepatic Alfaa — HFP appears more spe-
c i f ic (80% posi t iv i ty) despite 10% false 
positive results.'" 
ii) Beta -S-fetroprotein and Gamma -S-
fetoproteins are found in a wide variety of 
malignant and nonmalignant conditions. 
Specific data regarding these antigens is 
lacking at this time. 
iii) fetal sulfoglycoprotein antigen (ESA). 
In initial studies 75 of 78 patients with gastric 
carcinoma had elevated levels of ESA in their 
gastric ju ice." But there was no fall in ESA 
levels even after complete removal. FSA is 
elevated in 10-15% of benign gastric ulcers. 
CEA Positivity in Benign Disorders Table II 
Disease 
Incidence of Positive Assays 
Percentage No of Cases 
Alcoholic cirrhosis, severe 45 88 
Alcoholic pancreatitis 43 42 
Pulmonary tuberculosis 38 21 
Chronic bronchitis and emphysema 25 63 
Inflammatory bowel disease 21 95 
Diverticulitis and peptic ulcer 21 33 
Colorectal polyps 9 67 
Prostatic - hypertrophy 7 30 
Breast - fibroadenosis 7 70 
Gastric atrophy 5 19 
Norman Zamchek M. D. and Gabor Pusztaszeri M. D.; CEA, AFP 
and other potential tumor makers: CA-Cancer Journal for Clinicians, 
vol. 25, Na 4 July/August 1975. 
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iv) Carc inoplacenta l a lkal ine phos-
phatase is a nonspecific tumor marker and is 
found in highest frequency in ovarian (45%), 
test icular (40%) and pancreatic (30%) 
cancers.'^ 
v) Oncofetal antigens (OFA). In prelimin-
ary studies 29 of 30 patients with carcinoma 
ofthe pancreas had high levels of oncofetal 
antigens. Further work is needed to confirm 
the importance of this antigen.'^ 
Evidence for a successful 
immunological surveillance 
That immunological factors influence the 
natural course of certain tumors in man may 
be indirectly observed by comparing the 
incidence of neoplasia in immunosup-
pressed and normal populations. 
There is sufficient evidence that impair-
ment of immunological capacity increases 
the susceptibility to cancer and accelerates 
its growth'" (Table IV). The use of immu-
nosuppressive agents (part icular ly ant i -
lymphocytic serum) to prevent rejection of a 
grafted organ in man has provided further 
support for the existence of immunological 
surveillance that rids the body of incipient 
neoplastic cells. The incidence of neoplasia 
in patients with renal allograft transplant has 
been 20 to 80 limes higher than in general 
population.'" Most of these tumors are lym-
phoret icular , epi thel ia l or anaplastic in 
nature. 
Table III 








Hepatocellular carcinoma 180 72 
Testicular teratxarcinoma 101 75 
Pancreatic carcinoma 44 23 
Gastric carcinoma 91 18 
Colonic carcinoma 193 5 
Bronchogenic carcinoma 150 7 
Breast carcinoma 55 0 
Nonhepatic benign lesions 300 0.3 
Normal controls over 1 year of age 210 0 
From: Waldmann, LA., and Mcintire, K.R.: The use of radio-immunoassay 





The Incidence of Primary Cancer in Immunologically 
Deficient and Renal Transplant Patients 
Disease 
Percent Incidence 










Wiskott-Aldrich 10 Lymphoreticular 
Common variable immuno-
deficiency 
10 Lymphoreticular & 
carcinomas 
Isolated IgA - Adenocarcinoma of 
stomach (one case) 
Ataxia telangiectasia 10 Lymphoreticular, sarcoma, 
carcinoma 
Renal transplant patients 1.26(190/15,000) 
(25 X normal) 
Epithelial (62 percent) 
Mesenchymal (38 percent) 
•From Richard A. Gatti and Robert A. Good 
••From Olga Jonasson and Israel Penn and Thomas t Starzl 
Burnet' has studied denovo malignancies 
in 42 renal homograft recipients and came 
out with certain interesting points; viz: 
a) Patients tended to be of younger age 
(8-54 years) with a mean of 33 years. 
b) Al l had immunosuppression w i th 
azothiaprim and prednisone. 
c) 21 of 42 cases (50% ) had mesenchymal 
tumors (most common ly re t icu lum cel l 
sarcoma). 
d) Highly malignant tumor tends to appear 
much earlier after transplantation than the 
relatively low grade malignancies of skin, 
lips, etc. 
e) Average time of appearance of tumors 
after transplantation was 25 months. 
f) Thymus was not removed from any 
patient. 
g) Antilymphocytic globulin was given in 
10 of 42 patients. 
An unusual feature of lymphomas in this 
series was the frequency with which the 
brain was involved. Of 22 patients with 
lymphomas, the brain was involved in 11 and 
was the only organ involved in eight pa-
tients. There is enough evidence at least in 
animals that acceleration of metastasis is 
more frequent with azothiaprim and pred-
nisone therapy. '" This may be true in 
humans. 
Spontaneous cure of cancer 
Spontaneous cure of cancer has been a 
puzzling curiosity for many years. It suggests 
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yet another evidence for the existence of 
immunological surveillance. 
Everson and Cole studied 176 cases of 
cancer showing spontaneous regression. 
More than half fell into one of the four 
categories: a) malignant melanoma, b) neu-
roblastoma, c) carcinoma of kidney, or d) 
choriocarcinoma. Lymphomas, leukemias 
and soft tissue sarcomas are other examples 
of occasional regression. Though spon-
taneous regression does not unequivocally 
prove the presence of tumor specific anti-
gen, it is probably the most logical 
explanation. 
More direct evidence for spontaneous 
regression comes from histological findings. 
In breast cancer, a positive correlation exists 
between favorable prognosis and lymphoid 
in f i l t ra t ion around the tumor where the 
tumor is advancing and infiltrating. This 
lymphoid and plasma cellular reaction sug-
gests specific immunological reaction to 
some component of tumor growth. Similarly, 
highest survival rates w i th gastric car-
cinomas are associated with lymphoid infil-
t rat ion in the tumor itself and sinus 
histiocytosis around regional lymphnodes 
whether or not lymphnode metastasis is 
present. It is interesting that these considera-
tions have a higher correlation with survival 
than adequate surgical removal of tumor. 
The remarkably high cure obtained with 
chemotherapy in Burkitt's lymphoma and 
choriocarcinoma are attributed to concomi-
tant immunity against strong foreign cell 
surface antigens. The Epstein-Barr virus re-
lated antigen in Burkitt's lymphoma may be 
responsible for the occasional spontaneous 
regression seen. Where Burkitt's lymphoma 
is resistant to chemotherapy, the patients 
seem to accumulate an IGG layer on the 
plasma membrane. This globulin apparently 
renders the cells more immuno-resistant. 
The 70% cure rate seen in choriocarcinoma, 
particularly with methotrexate, appears to 
come from an effective immune response in 
these patients. 
Mechanisms of immunological failure 
Precancerous lesions in man can antedate 
the emergence of frank malignancy by years, 
ie: 
i) Intestinal polyps preceding colonic 
carcinoma. 
ii) Solarkeratosisand leukoplakis preced-
ing invasive squamous carcinoma. 
iii) Dysplastic squamous epithelium of 
cervix and bronchus converting into 
carcinoma cervix and bronchus. 
iv) Hydatiform moleconvertingtochorio-
carcinoma. 
Immunological surveillance in all these 
conditions does notalways prevent develop-
ment of tumor. So, what factors are responsi-
ble for escape of this immuno log ica l 
surveillance? Postulations are various.'-'" 
i) Cancer could be a consequence of an 
inherited selective defect in immu-
nological surveillance. Leukemia in-
duced by gross virus is seen in 100% of 
susceptible mice, only 1 % of resistant 
strains after exposure to 87 days in 
both groups. However, leukemia de-
veloped in 25% of resistant strains 
after 304 days when the immunologi-
cal surveillance was broken down.'^ 
ii) Since neoplasm generally grows from 
small foc i of cel ls, these may not 
provide sufficient antigenic stimulus at 
an early stage of tumor growth to el icit 
an immunological reaction. Therefore, 
they sneak through the immunological 
defense of the host. When the host is 
sensitized, it may be too late to attack 
an already established tumor. 
iii) Failure of immunological surveillance 
may be due to tumor specific antigen 
induc ing a state of immunolog ic 
tolerance. 
iv) TSA may be coated by substances such 
as sialomucin and, therefore, not rec-




As the latest modality of approach for 
treatment of neoplastic diseases, immuniza-
tion may be prophylactic against a tumor the 
patient is yet to encounter or therapeutic 
against one that is already growing. 
(1) Prophylactic immunization. The ulti-
mate goal of immunotherapy is prophylac-
tic. Experimental models have demonstrated 
the possibility of such immunization at two 
levels—the causative agent and the tumor 
specific antigen of neoplastic cel l . ' ' The 
most important target of this futuristic ap-
proach to therapy is the oncogenic viruses 
isolated from human tumor. But two basic 
problems face a prophylact ic vaccine 
against tumors: 
a) Each histologically different neoplasm 
appears to have a different TSA. So, a new 
vaccine would be necessary for each neo-
plasm arising from every organ site, eg, 
colon, breast, lung, etc. 
b) It is unlikely that all human tumors are 
caused by the same virus. So, a separate 
vaccine would be needed for each type of 
virally-induced neoplasm. 
In contrast, tumor vaccines based on non-
specific immunization might be feasible 
much sooner. Studies have shown that 
Bacille Calmette-Guerin (B.C.G.) signifi-
cantly decreased the development of many 
spontaneous tumors in several strains of 
m ice . " Therefore, nonspecific stimulation 
of immune response would have a greater 
advantage over specific vaccine, since, the-
oretically, it could be effective against all 
types of human neoplasia. Preliminary evi-
dence suggesting the validity of such a state-
ment comes from the work of Rosenthal and 
associates who reported a s igni f icant ly 
lower incidence of acute leukemia in chil-
dren receiving B.C.G. vaccine compared to 
control groups." 
(2) Therapeutic approach of malignancy 
may be: 
a) Nonspecific immunotherapy, 
b) Specific immunotherapy, or 
c) Adoptive transfer of immunity. 
(A) Nonspecific immunotherapy is an at-
tempt to stimulate the immune system with 
adjuvants that have no antigenic relation-
ship to the tumor. Several microbiological 
agents are shown to be capable of general 
stimulation of the lymphorecticular system. 
In current clinical trials the most commonly 
used materials are: '*-" 
1. B a c i l l u s of C a l m e t t e - G u e r i n 
(B.C.G.) 
2. Methanol extract ion residue of 
B.C.G. 
3. Corynebacterium parvum 
4. Levamasole 
5. Polynucleot ides and polysac-
charides 
In experimental models these agents have 
inhibited the development of spontaneous 
tumors, the induction of tumors by chemi-
cals and viruses and the growth of trans-
plantable tumors."^'" Nonspecific immu-
notherapy seems to promote both cell-medi-
ated and humoral immunity and may be 
effective in partially reversing the immu-
nosuppression due to tumor and chem-
otherapy. B.C.G. and corynebacter ium 
parvum are receiving the most extensive 
clinical trials at the present t ime." . B.C.G. 
trials are directed against mal ignant 
melanoma, acute leukemia and soft tissue 
sarcomas. In melanoma B.C.G. has pro-
duced up to 90% regression^" rate when 
injected intralesionally. The response to 
B.C.G. in melanoma occurs primarily in 
those w i t h disease l imi ted to skin, sub-
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cutaneous tissue and regional lymphnodes. 
Patients with metastasis to parenchymal 
organs such as lung, liver, and brain gener-
ally have little response to B.C.G.^"'^' 
Effects of B.C.G. in acute leukemia have 
mixed results. Mathe^' conducted a control-
led clinical test in 30 patients with acute 
lymphatic leukemia who are in complete 
remission fo l l ow ing intensive chem-
otherapy. Ten of these patients who received 
no further therapy relapsed within 130 days; 
the other 20 patients receive irradiated leu-
kemia cells, B.C.G. or both. There was a 
significant prolongation of survival in the 
latter group. But, studies carried out by 
Childrens' Cancer Study Group A showed 
that the group maintained with drugs had 
relatively longer durations of remission than 
either the control group or B.C.G.-treated 
group. Results of further studies are awaited. 
Initial trials of B.C.G. in acute myelogenous 
leukemia are encouraging." 
Besides intralesional injection, B.C.G. has 
also been given by aerosol inhalation post-
operatively to patients with lung cancer. In 
addition B.C.G. has been introduced into the 
pleural space subsequent to lung resection 
in orderto reproduce the beneficial effects of 
postoperative empyema. But it is too early to 
evaluate the c l in ica l value of these ap-
proaches. Systemic administration of B.C.G. 
has also been studied" as many cancers are 
already disseminated by the time of diag-
nosis. In patients w i th leukemia and 
melanoma, B.C.G. has also been used either 
by scarification or the multiple puncture 
method." 
Mechanism of act ion of B.C.G. Why 
should the injection of B.C.G. cause a tumor 
to regress? The answer is not entirely clear, 
but it is known that B.C.G. induces a local 
sustained granulomatous inflammatory re-
sponse." ' " As part of this response, various 
cytotoxic substances are released and all 
cells in the immediate vicinity of the tumor, 
as well as normal cells, may be damaged or 
destroyed. In addition, macrophages acti-
vated into a state of increased phagocytic 
and metabol ic function seem to be able to 
kill tumor cells. 
(B) Spec;f/c immunotherapy employs sub-
stances that are antigenically related to or 
products of the tumor, such as killed tumor 
cells from the same patient or from another 
patient with antigenically similar tumor. 
The approach most widely studied is to 
alter the tumor cells with neuraminidase. 
This enzyme removes the coating of sialic 
acid that coats many of the tumor cells, 
rendering the tumor more immunogenic. 
Active specific immunotherapy may also 
include the use of soluble tumor antigen 
extracts prepared from tumor obtained at 
surgery or at autopsy. Another approach is to 
stimulate the patient's lymphocytes with his 
own tumor cells (or antigen) by cultivating 
them together in vitro. The lymphocytes 
immunized in vitro can then be reinfused 
into the patient, where they may have an 
increased capacity to interact with tumors. 
(C) The adoptive transfer of immunity 
involves transfer of specific immunity from 
one individual to another. Two sources of 
material, transfer factor and immune RNA, 
appear to be capable of transferring immu-
nological information. Both transfer factor 
and immune RNA can be used to stimulate 
lymphoid cells in vitro or they may be 
injected directly into the recipient. 
Transfer factor is a cell-free leukocyte 
extract capable of transferring delayed hy-
persensitivity." It resists digestion by endo-
genous nucleases, lysosomal hydrolase, 
deoxyribonuclease and ribonuclease. It is 
dialysable. Transfer factor is neither anti-
genic nor an immunoglobulin fragment and 
has a molecular weight of less than 10,000. 
M9 
Radhakrishna 
Transfer factor has been used in a wide 
variety of disorders" both malignant and 
non-malignant, commonly where there is an 
immunodeficient state. The various disor-
ders in which transfer factor is useful are 
shown in Table V. 
TABLE V 


















(Modified From: 'Therapeutic Uses of 
Transfer Factor" by 
H. H. Eudenberg et al Hospital Practice 
January 1974 
Immune R N A ' s " ' " exact mechanism in 
transfer of immunity is unknown. The the-
oretical advantages in support of adoptive 
immunotherapy with immune RNA are: 
i) If it is not of itself antigenic even 
after repeated injections, second-
ary syndromes or immune elimina-
tions would not be expected to 
occur. 
ii) There is no danger of inducing a 
graft versus host reaction in the 
immunosuppressed host. 
The potential sources of immune 
RNA are: 
i) From lymphocytes of patients who 
have been cured of tumor or who 
have undergone spontaneous 
regression. 
ii) From animals that have been speci-
f ica l ly immunized w i t h human 
tumor. 
Immune RNA has been used in renal cell 
carcinoma with some success. Pilch et al 
reviewed results of xenogenic RNA immu-
notherapy in 17 patients with various malig-
nancies." One patient showed improve-
ment and had stabilization of disease. The 
studies with immune RNA" are still in early 
stages and further trials are needed to assess 
the value of this form of immunotherapy. 
There have been no toxic reactions reported 
with immune RNA. The major hazard is 
thought to be potential sensitization to sheep 
protein and subsequent prophylaxis. Some 
patients may have slight discoloration of the 
sk in . " - " 
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